References
- Anderson H, Lund B, Bach F, et al (1994). Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 12, 1821-26.
- Androulakis N, Kouroussis C, Kakolyris S, et al (1998). Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study. Ann Oncol, 9, 1127-30. https://doi.org/10.1023/A:1008497322508
- Barlesi F, Jacot W, Astoul P, et al (2006). Second line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer, 51, 159-72 https://doi.org/10.1016/j.lungcan.2005.08.017
- Bhatia S, Hanna N, Ansari R, et al (2009). A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer, 38, 73-77.
- Bonomi P, Paz-Ares L, Langer C, et al (2005). Xyotax versus docetaxel for the second-line treatment of non-small-cell lung cancer: the STELLAR 2 phase III study. Lung Cancer, 49, S35.
- Bunn PA Jr, Kelly K (1998). New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 4, 1087-90.
- Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in A-NSCLC: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
- Caponi S, Vasile E, Ginocchi L, et al (2010). Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clin Lung Cancer, 11, 320-7. https://doi.org/10.3816/CLC.2010.n.040
- Comellaa P, Chiurib EC, Cataldisc G, et al (2010). Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer A randomized phase II SICOG trial. Lung Cancer, 68, 94-98 https://doi.org/10.1016/j.lungcan.2009.05.008
- Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6. https://doi.org/10.1007/s12032-007-9005-3
- Crino L, Scagliotti G, Marangolo M, et al (1997). Cisplatingemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 15, 297-03.
- Crino L, Mosconi AM, Scagliotti G, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol, 17, 2081-85.
- Cullen M (2006). Second-line treatment options in advanced nonsmall cell lung cancer: current status. Semin Oncol, 33, S3-S8. https://doi.org/10.1053/S0093-7754(06)00402-7
- Cullen MH, Zatloukal P, Sorenson S, et al (2008). A randomized phase III trial comparing standard and high dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 19, 939-45. https://doi.org/10.1093/annonc/mdm592
- Delbaldo C, Michiels S, Syz N, et al (2004). Benefit of adding a drug to a single agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA, 292, 470-84. https://doi.org/10.1001/jama.292.4.470
- De Marinis F, Grossi F (2008). Clinical evidences for second-and third-line treatment options in advanced non-small cell lung cancer. Oncologist, 13, 14-20.
- De Marinis F, Ricciardi S (2011). Second-line treatment options in advanced non-small cell lung cancer. Eur J Cancer, 47, S258-71.
- Di Maio M, Lama N, Morabito A, et al (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer, 46, 735-43. https://doi.org/10.1016/j.ejca.2009.12.013
- Di Maio M, Chiodini P, Georgoulias V, et al (2009). Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-smallcell lung cancer. J Clin Oncol, 27, 1836-43. https://doi.org/10.1200/JCO.2008.17.5844
- Douillard JY, Shepherd FA, Hirsh V, et al (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 28, 744-52. https://doi.org/10.1200/JCO.2009.24.3030
- Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum- containing chemotherapy regimens. J Clin Oncol, 18, 2354-62.
- Gatzemeier U, Heckmayer M, Neuhauss R, et al (1995). Chemotherapy of advanced noperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol, 22, 24-8.
- Gebbia V, Gridelli C, Verusio C, et al (2009). Weekly docetaxel vs. docetaxel-based combination chemotherapy as secondline treatment of advanced nonsmall-cell lung cancer patients: The DISTAL-2 randomized trial. Lung Cancer, 63, 251-8. https://doi.org/10.1016/j.lungcan.2008.05.027
- Georgoulias V, Kouroussis C, Agelidou A, et al (2004). Irinotecan plus gemcitabine vs irinotecan for the secondline treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: A multicentre, randomised, phase II study. Br J Cancer, 91, 482-8. https://doi.org/10.1038/sj.bjc.6602010
- Georgoulias V, Agelidou A, Syrigos K, et al (2005). Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer, 93, 763-9. https://doi.org/10.1038/sj.bjc.6602748
- Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res, 9, 4535-8.
- Gridelli C, Ardizzoni A, Ciardiello F, et al (2008). Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 3, 430-40 https://doi.org/10.1097/JTO.0b013e318168c815
- Grilli R, Oxman AD, Julian JA (1993). Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol, 11, 1866-72.
- Hainsworth JD, Thompson DS, Greco FA (1995). Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol, 13, 1609-14.
- Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
- Huang CH, Millenson MM, Sherman EJ, et al (2008). Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. J Thorac Oncol, 3, 1032-8 https://doi.org/10.1097/JTO.0b013e31818307c2
- Isla D, Rosell R, Sánchez JJ, et al (2001). Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol, 19, 1071-7.
- Kim ES, Hirsch V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST): A randomised phase III trial. Lancet, 372, 1809-18. https://doi.org/10.1016/S0140-6736(08)61758-4
- Klastersky J, Awada A (2012). Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol, 81, 49-57.
- Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane+platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.
- Kosmidis PA, Kalofonos HP, Christodoulou C, et al (2008). Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol, 19, 115-22.
- Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T (2007). Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced nonsmall cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol, 60, 189-95 https://doi.org/10.1007/s00280-006-0360-0
- Paz-Ares L, Ross H, O'Brien M, et al (2008). Phase III trial comparing paclitaxel poliglumex vs. docetaxel in the secondline treatment of non-small-cell lung cancer (NSCLC). Br J Cancer, 98, 1608-13. https://doi.org/10.1038/sj.bjc.6604372
- Pectasides D, Pectasides M, Farmakis D, et al (2005). Comparison of docetaxel and docetaxelirinotecan combination as secondline chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. Ann Oncol, 16, 294-9. https://doi.org/10.1093/annonc/mdi053
- Pino MS, Gamucci T, Mansueto G, et al (2008). A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weeklypaclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 60, 381-6. https://doi.org/10.1016/j.lungcan.2007.10.027
- Reck M, van Zandwijk N, Gridelli C, et al (2010). Erlotinib in advanced non-small cell lung cancer - efficacy and safety findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. J Thorac Oncol, 5, 1616-22. https://doi.org/10.1097/JTO.0b013e3181f1c7b0
- Scagliotti G, Hanna N, Fossella F, et al (2009). The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist, 14, 253-63. https://doi.org/10.1634/theoncologist.2008-0232
- Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22. https://doi.org/10.1097/00001622-199303000-00010
- Shepherd FA, Abratt R, Crino L, et al (2000). The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer, 30, 117-25. https://doi.org/10.1016/S0169-5002(00)00135-5
- Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
- Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
- Smit EF, van Meerbeeck JPAM, Lianes P, et al (2003). Three-arm randomized study of two cisplatin-based regimen and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group- EORTC 08975. J Clin Oncol, 3, 3909-17.
- Smit EF, Groen HJ, Smit HJ, et al (2008). A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)-NVALT 7. J Clin Oncol, 26, 436.
- Socinski MA, Steagall A, Gillenwater H (1999). Secondline chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest, 17, 181-8. https://doi.org/10.3109/07357909909021419
- Stinchombe TE, Socinski MA (2008). Considerations for secondline therapy of non-small cell lung cancer. Oncologist, 13, 28-36 https://doi.org/10.1634/theoncologist.13-S1-28
- Takeda K, Negoro S, Tamura T, et al (2009). Phase III trail of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: Results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol, 20, 835-41. https://doi.org/10.1093/annonc/mdn705
- Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet, 366, 1527-37. https://doi.org/10.1016/S0140-6736(05)67625-8
- Treat J, Belani CP, Edelman MJ, et al (2005). A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced stage IIIB IV non-small cell lung cancer (NSCLC). Update on the Alpha oncology trial (A1-99002L). Proc Soc Am Clin Oncol, 23, 627.
- Tucker S (2010). The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. Curr Drug Targets,11, 58-60. https://doi.org/10.2174/138945010790031036
- Vamvakas L, Angelaki S, Kentepozidis NK, et al (2010). Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol, 28, 15s
- Wachters FM, Groen HJ, Biesma B, et al (2005). A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV nonsmall- cell lung cancer who failed first-line treatment. Br J Cancer, 92, 15-20. https://doi.org/10.1038/sj.bjc.6602268
- Walling J (1994). Chemotherapy for advanced non-small-cell lung cancer. Respir Med, 88, 649-57. https://doi.org/10.1016/S0954-6111(05)80061-7